373 related articles for article (PubMed ID: 33197601)
1. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
[TBL] [Abstract][Full Text] [Related]
2. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
Zou P; Chen Z; He Q; Zhuo Y
Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.
Ghoochani A; Hsu EC; Aslan M; Rice MA; Nguyen HM; Brooks JD; Corey E; Paulmurugan R; Stoyanova T
Cancer Res; 2021 Mar; 81(6):1583-1594. PubMed ID: 33483372
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration‑resistant prostate cancer.
Yang Y; Liu T; Hu C; Xia H; Liu W; Chen J; Wu S; Jiang Y; Xu Y; Liu W; Zhao L
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649848
[TBL] [Abstract][Full Text] [Related]
6. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
[TBL] [Abstract][Full Text] [Related]
8. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
9. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.
Hou ZJ; Luo X; Zhang W; Peng F; Cui B; Wu SJ; Zheng FM; Xu J; Xu LZ; Long ZJ; Wang XT; Li GH; Wan XY; Yang YL; Liu Q
Oncotarget; 2015 Mar; 6(8):6326-40. PubMed ID: 25811972
[TBL] [Abstract][Full Text] [Related]
10. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
[TBL] [Abstract][Full Text] [Related]
12. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
13. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy.
Lin S; Yang L; Yao Y; Xu L; Xiang Y; Zhao H; Wang L; Zuo Z; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jul; 38(1):293. PubMed ID: 31287013
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition.
You JH; Lee J; Roh JL
Cancer Lett; 2021 Jun; 507():40-54. PubMed ID: 33741422
[TBL] [Abstract][Full Text] [Related]
16. Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC).
Du Y; Shuai Y; Liu Z; Li H; Yin Y
Mol Biotechnol; 2024 May; 66(5):1220-1228. PubMed ID: 38103098
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
[TBL] [Abstract][Full Text] [Related]
18. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
19. Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer.
Ma X; Zou L; Li X; Chen Z; Lin Z; Wu X
Cancer Biother Radiopharm; 2019 Apr; 34(3):181-188. PubMed ID: 30855185
[TBL] [Abstract][Full Text] [Related]
20. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.
Michaelis M; Agha B; Rothweiler F; Löschmann N; Voges Y; Mittelbronn M; Starzetz T; Harter PN; Abhari BA; Fulda S; Westermann F; Riecken K; Spek S; Langer K; Wiese M; Dirks WG; Zehner R; Cinatl J; Wass MN; Cinatl J
Sci Rep; 2015 Feb; 5():8202. PubMed ID: 25644037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
